NurExone Biologic Inc.
NRXBF
$0.47
$0.025.28%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 8.83% | -5.24% | 9.77% | -17.20% | -39.32% |
| Total Depreciation and Amortization | 40.48% | 30.23% | 35.90% | 161.11% | 223.08% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 60.38% | 41.21% | 8.41% | 4.11% | -2.19% |
| Change in Net Operating Assets | -60.85% | -90.48% | 65.60% | -298.98% | 247.54% |
| Cash from Operations | 10.40% | -25.35% | 32.33% | -56.97% | -22.64% |
| Capital Expenditure | 200.00% | 93.75% | 80.43% | 96.01% | 96.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 200.00% | 93.75% | 80.00% | 96.01% | 97.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -800.00% | -166.67% | -42.86% | 0.00% | 85.71% |
| Issuance of Common Stock | -72.91% | -30.67% | 56.30% | -- | 10,506.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -71.38% | -31.32% | 1,183.62% | -15.65% | 3,513.64% |
| Foreign Exchange rate Adjustments | -90.76% | -275.00% | 130.00% | -450.00% | 340.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -178.75% | -460.71% | 163.36% | -277.54% | 173.56% |